Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $58.00 Consensus Price Target from Brokerages

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $58.00.

IMCR has been the topic of several recent research reports. Oppenheimer lifted their price target on Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. HC Wainwright reiterated a "buy" rating and set a $100.00 target price on shares of Immunocore in a report on Monday, June 2nd. Wall Street Zen downgraded Immunocore from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Immunocore in a report on Tuesday, May 27th. They issued a "buy" rating and a $65.00 price objective for the company.

Hedge Funds Weigh In On Immunocore

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in shares of Immunocore by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 35,492 shares of the company's stock worth $1,047,000 after acquiring an additional 420 shares during the last quarter. Virtus Investment Advisers LLC lifted its position in Immunocore by 5.3% during the second quarter. Virtus Investment Advisers LLC now owns 12,472 shares of the company's stock worth $391,000 after acquiring an additional 625 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in shares of Immunocore by 1.1% during the first quarter. Envestnet Asset Management Inc. now owns 67,259 shares of the company's stock worth $1,996,000 after acquiring an additional 735 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Immunocore in the fourth quarter valued at approximately $25,000. Finally, Orion Porfolio Solutions LLC increased its stake in shares of Immunocore by 4.5% during the second quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company's stock worth $752,000 after purchasing an additional 1,031 shares during the period. Institutional investors own 84.50% of the company's stock.

Immunocore Trading Up 0.3%

Shares of NASDAQ IMCR traded up $0.11 during midday trading on Monday, reaching $32.78. 23,875 shares of the stock were exchanged, compared to its average volume of 336,179. The company has a debt-to-equity ratio of 1.01, a current ratio of 5.89 and a quick ratio of 5.86. Immunocore has a 12 month low of $23.15 and a 12 month high of $39.33. The business has a 50-day simple moving average of $33.33 and a two-hundred day simple moving average of $31.26. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of -82.14 and a beta of 0.77.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01. The firm had revenue of $130.65 million for the quarter, compared to analyst estimates of $122.96 million. Immunocore had a negative return on equity of 5.40% and a negative net margin of 5.70%.The company's revenue for the quarter was up 30.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.23) earnings per share. As a group, equities research analysts expect that Immunocore will post -0.94 EPS for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.